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Attempts at developing oncolytic viruses have been primarily based on rational design. However, this approach has been met with
limitedsuccess.Analternativeapproachemploysdirectedevolutionasameansofproducinghighlyselectiveandpotentanticancer
viruses. In this method, diverse viruses are grown under conditions that maximize diversity and then passaged under conditions
meant to mimic those encountered in the human cancer microenvironment. Viruses which evolve to thrive under this selective
pressure are isolated and tested to identify those with increased potency (i.e., ability to replicate and spread) and/or an increased
therapeutic window (i.e., diﬀerentiated replication and spread on tumor versus normal cells), both of which have potential value
but the latter of which deﬁnes an oncolytic virus. Using ColoAd1, an oncolytic virus derived by this approach as a prototype,
we highlight the beneﬁts of directed evolution, discuss methods to “arm” these novel viruses, and introduce techniques for their
genetic modulation and control.
1.Introduction
As our understanding of cancer increases, the complex
nature of this disease which often involves multiple muta-
tions, overlapping signaling pathways, and the ability to
adaptanddevelopresistancetovarioustherapeuticsbecomes
more evident [1–3]. Such a complex disease necessitates
equally complex therapies—such as oncolytic viruses [4].
By deﬁnition, these viruses infect and selectively replicate in
tumor cells resulting in eventual cell lysis. This replication
and lysis serves to eradicate the target tumor cells while
amplifying the therapeutic in a tumor-dependent fashion, all
the while sparing neighboring normal cells. Unfortunately,
the promise of oncolytic viruses as agents that selectively
ﬁnd and kill tumor cells has not been fully realized [5–
8]. This fact may be due in part to some prejudices taken
by researchers in their pursuit of oncolytic viruses. For
example, the majority of oncolytic viruses currently studied
are Ad5 based primarily, because Ad5 has been widely
characterized and methods for its genetic manipulation are
well established, making it the practical starting point for
most studies. However, there is no clear rationale why Ad5
would make a superior oncolytic virus as opposed to other
Ad serotypes or other viral classes. Additionally, the genetic
manipulation of today’s viruses in an attempt to increase
selectivity and or potency may be misguided due to our
limited knowledge of the underlying causes and nature of
cancer. Therefore, the plasticity and complexity of tumors
may hinder the rational design of oncolytic viruses [9].
In an attempt to circumvent these issues, researchers are
beginning to explore the use of directed evolution as a way to
harness thepower of natural selection and to derive desirable
properties without concern for the mechanism(s) responsi-
ble for these properties [10–12]. Directed evolution is not a
foreign concept in the ﬁeld of virology and has been utilized
as a way to modulate viral vectors and enhance gene delivery.
Such experiments focus primarily on enhancing infectivity
or modulating tropism by changes to the viral coat [13, 14].
For oncolytic viruses, the goal is obviously diﬀerent, namely
to drive the viruses to evolve for optimal proliferation in the
tumor environment. Normally, viruses infect normal cells.
For Adenoviruses, this is via an oral or nasal route of entry
and involves the epithelial lining of the nose, throat, and/or
gutresultinginarespiratoryand/orgastrointestinalinfection
(Figure 1(a)). As a cancer therapy, the objective is to develop
viruses that selectively infect a vastly diﬀerent set of cells,2 Advances in Virology
namely, transformed epithelial cells and tumor associated
endothelium located in distinct locations throughout the
body, most of which are not normally seen during the typical
Adenovirus infection. Researchers are therefore asking a
oncolytic virus to eﬃciently and selectively kill cells to which
they would never normally be exposed (Figure 1(b)). The
necessary biological alterations needed to reach this goal
are complex, but unlike evolution in nature which takes an
extended period of time for adaptations resulting in new and
desirable traits to accumulate, directed evolution can quickly
lead to the rise of novel “species”. Importantly, directed
evolution is dependent on 2 factors both of which are
completelywithintheinvestigator’scontrol,namely,theneed
for (1)) a diverse starting pool and (2)) selective pressure
designed to favor a speciﬁc outcome. To maximize starting
diversity,theresearcherhasamyriadofoptionsrangingfrom
a single mutated serotype to entire viral classes. Additionally,
theabilityofvirusestoundergorecombinationundercertain
conditions can increase this starting diversity. Similarly,
the directed outcome (increased tumor proliferation) is
determined by the selective pressure set by the experimental
setup and can be modulated in a number of ways including
the source of the tumor cells and growth conditions.
2. ColoAd1
Human Adenovirus is comprised of 56 serotypes which
are subdivided into groups A–G. These serotypes diﬀer
in a number of ways (e.g., pathology, hemagglutination
properties, and cellular receptors used for entry) which help
to distinguish them from one another and determine their
group aﬃliation. Despite the diversity of human adenovirus,
the majority of all oncolytic viruses are Ad5-based leaving
the other serotypes and their oncolytic potential untapped.
Onewaytoexplorethesealternativeserotypesisvia“directed
evolution”. In this approach, Ad serotypes, representing
the diﬀe r e n tA ds u b g r o u p s ,a r ep o o l e da n dp a s s a g e da ta
high multiplicity of infection on human tumor cell lines
representative of the target indication. This process invites
recombination and creates selective pressure that gives rise
to highly potent viral variants.
When this approach was applied to the colon cancer
cell line, HT29, the result was ColoAd1, the ﬁrst non-Ad5-
based and ﬁrst directed-evolution-derived oncolytic virus
[10]. Chromatographic and sequence analysis revealed that
ColoAd1 was Ad11p, a group B virus, with a nearly complete
E3 region deletion, a smaller deletion in the E4 region, and
a chimeric Ad3/Ad11p E2B region [10, 15]. In vitro studies
showed ColoAd1 to be 2-3 logs more potent than either of
its parent serotypes (Ad11p and Ad3), the standard Ad5,
or the most clinically advanced oncolytic Ad, ONYX-015
[10, 16] Importantly, this increase in potency on cancer
cells did not translate to increased potency on normal
cells resulting in a therapeutic window that is 3-4 logs
greater than Ad5 or Onyx-015. These in vitro results were
supported by in vivo studies in a colon cancer liver seeding
xenograft model and ex vivo on tumor tissue isolates from
colon cancer patients. Parallel studies identiﬁed CD46 as
a cellular attachment receptor for Ad11p, the parent virus
of ColoAd1 [17, 18]. Interestingly, immunohistochemical
studies staining for CD46 expression on excised colon cancer
material,normallivertissueandnormalcolontissuerevealed
that strong CD46 staining was consistently seen in colon
cancer tissue but was absent or weak in normal colon and
liver tissue [10]. This suggests that CD46 expression may
be a contributing factor to the observed tumor selectivity
of ColoAd1. Importantly, CD46 overexpression has been
described for a number of diﬀerent cancer indications [19,
20], supporting the therapeutic value of this oncolytic virus.
Theoretically, CD46 screening of tumor tissue could help
guide physicians to identify which patients should be treated
with this agent.
3. Manipulation andControl of Novel Viruses
Oncolytic viruses can and have been used to deliver exoge-
nous genetic material, giving them much needed ﬂexibility
and complexity as a cancer treatment and augmenting their
potential as viable cancer therapies [21]. The ability to
engineer the genome of a replicating virus to carry foreign
material is referred to as “arming”. This strategy has been
used in a variety of ways to alter viral selectivity, potency,
safety, and utility [22, 23].
Likenonreplicatingviruses,earlyarmedoncolyticviruses
controlled expression of foreign genes by using an exogenous
constitutive or conditional promoter. This approach allowed
for high levels of expression and, in the case of conditional
promoters, some level of speciﬁcity. As the ﬁeld advanced,
researchersdemonstratedthatexpressionofexogenousgenes
could be achieved by using the endogenous expression
machinery of the virus itself [24–26]. This latter method
proved to have some advantages, the ﬁrst being that it
decreased the size of the foreign DNA that could be inserted
into the viral genome. This outcome was beneﬁcial given
that viruses have genomic size constraints that greatly eﬀect
packaging eﬃciency. The second advantage of utilizing
endogenous expression machinery is that depending on
the endogenous promoter used, the timing and level of
expression of the foreign gene could be controlled [24–
26]. This not only allowed for eﬃcient expression of the
exogenous gene but could be used as an added measure of
safety. Because the level of expression could be modulated
depending on the endogenous promoter used, researchers
and clinicians could have greater control over the levels
of the armed therapeutic/exogenous gene. Furthermore, by
utilizing an endogenous late promoter, it is possible to
limit the expression of the gene to late in the viral cycle
which, presumably, for an oncolytic virus would never be
reached in a nonpermissive cell (normal cell) and, therefore,
conﬁne expression only to target cancer cells. Importantly,
an armed therapeutic virus can express multiple genes [27]
that potentially increase the therapeutic beneﬁt of the virus
and/or enable the treating physician with the opportunity to
track the virus location (e.g., via imaging [28]) and viability
(e.g.,throughtheexpressionofaproteinthatcanbedetected
in the blood or is secreted from the treated patient), as a
means to better understand when additional treatments are
warranted.Advances in Virology 3
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Figure 1: Why we need directed evolution. (a) The starting point of all oncolytic viruses are naturally occurring viruses which infect normal
cells they encounter along their standard route of entry. (b) The goal is to develop oncolytic viruses which selectively infect and replicate in
cells they would never naturally encounter.
Arming is traditionally carried out by manipulating the
viralgenomeandusuallycallsforawellcharacterizedsystem.
The novel viruses resulting from directed evolution will
make rational insertion of therapeutic moieties extremely
challenging, especially when one considers that they would
not want to negatively impact the replication capabilities
of these viruses which are critical to their clinical beneﬁt.
Clearly, innovative approaches will need to be taken in order4 Advances in Virology
to manipulate viruses derived in this manner to ensure
that this does not occur. One such approach taken uses
a transposon-based method to “scan” a viral genome for
insertion sites which are compatible with the viral lifecycle
[29]. This approach makes it possible to arm these novel
viruses with exogenous genes expressed from a foreign
promoter or by the inclusion of a splice acceptor from an
endogenouspromoter[30].Althoughthismethod,likemany
advances in the oncolytic ﬁeld, was originally developed on
Adenoviruses, it can be extended to any number of viral
species whose genome can be cloned into a plasmid.
Given the potential to derive potent novel viruses from
the directed evolution approach, it is very important to keep
safety in mind. If these novel viruses are ever to advance as
therapeutics, having the ability to control their replication
in the treated patient is paramount. To this end, two
approaches were taken with ColoAd1. The ﬁrst was to study
the eﬀect on ColoAd1 of two clinically approved antivirals,
ribovirin (RBV), and cidofovir (CDV), and the second
was to genetically introduce drug sensitivity to the virus by
inserting the HSV TK gene into the ColoAd1 genome using
the transposon method [31].
Although there are no approved anti-Ad treatments,
both RBV and CDV have been used to experimentally treat
Adenoviral infections [32–34]. From these studies, RBV was
found to be eﬀective on Group C Ads but less so on Group B
Ads [35, 36]. Not surprisingly, ColoAd1, being derived from
2 group B viruses was refractory to RBV treatment. CDV
has been shown to have better Anti-Ad activity than RBV
and when used to treat ColoAd1 was eﬀective at inhibiting
viral replication and spread on both tumor and normal cell
lines. Interestingly, ColoAd1 was more sensitive to CDV
treatment than either of its 2 parental strains, Ad11p or
Ad3 suggesting that this increased CDV sensitivity was an
outcome of the directed evolution process and not simply
an inherited trait [31]. An alternative approach to the use of
approved antivirals is the insertion of the HSV TK gene into
the viral genome to create sensitivity to the approved drug
ganciclovir (GCV) [37]. This approach, made possible by the
transposon method of arming was successful in inhibiting
ColoAd1 infection of both tumor and normal cells [29, 31].
The potential for using TK expression to track the virus also
makes this approach appealing [38]. From these studies, it
wasdemonstratedthatColoAd1 couldbecontrolledthrough
outside intervention.
The value gleaned from the ColoAd1 experience goes
beyond a promising therapeutic, as it validates a new
approach for the oncolytic virus ﬁeld. The directed evolution
method that resulted in ColoAd1 could be applied to
other cancer types and other viral families. By utilizing
this method, researchers are not longer limited to well
characterized systems. Moreover, the ease by which viruses
are molecularly manipulated need not be the deciding factor
for proceeding. Although Adenoviruses have been covered in
this paper, this approach is amendable to all viral families
andopensupthepossibilityofharnessinginherentandnovel
oncolytic properties from a multitude of human viruses.
Unlike more deliberately designed approaches, directed
evolution capitalizes on the complexity of the tumor and can
be directed towards an outcome that depends predominantly
on the selective pressure applied by the researcher. Similar
to Ad5-based oncolytic viruses, it is possible to arm these
novel viruses without interfering with their lifecycle, thus
unlocking the potential to modulate their characteristics or
utility. Because these viruses are potentially highly potent,
developing ways to control their replication should be a
priority.
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